U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07946575) titled 'A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants' on Nov. 12.

Brief Summary: The primary purpose of this study is to evaluate the effect of quinidine sulfate on the pharmacokinetics (PK) of NAL ER in healthy participants.

Study Start Date: Nov. 03

Study Type: INTERVENTIONAL

Condition: Healthy Participants

Intervention: DRUG: NAL ER

Oral tablets

DRUG: Quinidine Sulfate

Oral tablets

Recruitment Status: RECRUITING

Sponsor: Trevi Therapeutics

Published by HT Digital Content Services with permission from Health Daily Digest....